Life expectancy in ovarian cancer: why early diagnosis changes everything
Ovarian cancer is one of the most complex oncological conditions in gynaecology, not only because of its biology but because of how it usually presents. Unlike other tumors, its early evolution is silent, which directly conditions life expectancy. In this article, Dr. Juan José Torrent, founder of the Quenet Torrent Institute, reviews the figures we manage today, the factors that genuinely change the prognosis and why the centre where the disease is treated weighs as heavily as the moment of diagnosis.
Today we know that talking about survival in ovarian cancer is not talking about a single figure: it is talking about a clinical scenario that changes radically depending on the moment of diagnosis.
The impact of stage on survival
When the ovarian tumor is detected in a localised stage, confined to the ovary, five-year survival exceeds 90-95%. This places early-stage ovarian cancer among the tumors with the best prognosis in gynaecological oncology.
However, this is not the most common scenario. In clinical practice, a large proportion of patients are diagnosed when the disease has already spread through the abdominal cavity or beyond, forming a peritoneal carcinomatosis of ovarian origin. In these cases, corresponding to stages III and IV, five-year survival drops to roughly 20-40%.
This difference is not marginal: it completely defines the course of the disease and explains why early diagnosis remains the central challenge.
A tumor that is hard to detect in time
Ovarian cancer rarely produces specific symptoms in its early stages. Sensations such as abdominal bloating, digestive changes or pelvic discomfort can appear subtly and be mistaken for benign processes. This lack of clear signals, combined with the absence of effective screening programmes for the general population, contributes to delayed diagnosis.
From a clinical perspective, this calls for a more proactive approach in patients with risk factors or above certain ages, where gynaecological follow-up takes on a strategic role. We expand on this in our guide on how to detect ovarian cancer and its diagnostic tests.
The importance of treatment in specialised centres
In recent years, scientific evidence has confirmed that treatment in highly specialised centres directly influences survival. It is not just about access to advanced technology, but about the accumulated experience in complex oncological surgery and in multidisciplinary decision-making.
The quality of the initial surgery, especially the ability to achieve complete tumor resection through open surgery or, where appropriate, robotic surgery, is one of the most relevant prognostic factors. Add to this the development of targeted therapies and new lines of treatment, alongside the integration of molecular analysis, which allows the strategy to be tailored to the biological characteristics of the tumor.
At the Quenet Torrent Institute we integrate within a single team advanced oncological surgery, medical oncology, molecular diagnostics and access to innovative therapies such as HIPEC (hyperthermic intraperitoneal chemotherapy), which is essential when peritoneal dissemination of ovarian origin is present.
Dr. Juan José Torrent
Founder & Oncological Surgeon
Quenet Torrent Institute
"Early-stage ovarian cancer has a survival rate above 90%, but outcomes decline sharply in advanced disease."
— American Cancer Society
"The prognosis of ovarian cancer does not depend solely on stage, but on how it is approached from the very first moment. The combination of expert surgery, molecular diagnosis and a personalised strategy is what truly changes the patient's evolution."
— Oncology Team, Quenet Torrent Institute
Beyond the figures: personalised medicine
Although stage is the single most decisive factor, it is not the only one. Tumor biology, response to treatment and the patient's genetic profile — including BRCA1/BRCA2 mutations — also have a decisive influence. And, above all, we can perform a high-quality surgery — the only prognostic factor we can directly influence — within new strategies such as HIPEC, targeted therapies and innovative regimens that we continuously evaluate from our clinical research line.
That is why life expectancy is no longer interpreted as an isolated statistic, but as the result of an individualised therapeutic strategy.
When the disease affects the peritoneum, we are speaking of peritoneal carcinomatosis of ovarian origin, where the combination of complete cytoreductive surgery plus HIPEC has reshaped survival curves compared with systemic chemotherapy alone.
Conclusion
Ovarian cancer remains a challenge for surgery and oncology, but also a field where advances are making a real difference. The key is still early diagnosis, but also surgery in the hands of the best experts and access to specialised treatment from the outset.
In this context, life expectancy is not just a statistic, but a reflection of how and where the disease is treated. If you need a second opinion on a diagnosis or treatment plan, the Quenet Torrent Institute team is available to evaluate your case and propose the best individualised strategy.
Frequently asked questions
What is the life expectancy in ovarian cancer?
Life expectancy in ovarian cancer varies significantly depending on the stage at diagnosis. In early stages it can exceed 90-95% at five years, while in advanced stages it drops to roughly 20-40%.
Why does early diagnosis matter so much?
Because it directly determines the prognosis. When the cancer is detected confined to the ovary, survival probabilities are very high. By contrast, when diagnosed in advanced stages, the disease has usually spread through the abdominal cavity and is much harder to treat.
Can ovarian cancer be cured?
Yes, particularly in early stages, where treatment can be curative in many cases. In advanced stages, although roughly 20% of patients can be cured, the goal is usually to control the disease and improve quality of life with prolonged survival.
What symptoms does ovarian cancer cause in early stages?
In early stages it usually causes no clear symptoms. It may present with non-specific signals such as abdominal bloating, pelvic discomfort or subtle digestive changes that are easily mistaken for benign conditions. This makes early detection difficult.
Is there an effective screening test?
There is currently no universally effective screening method for the general population. However, regular gynaecological follow-up and individualised risk assessment (family history, BRCA1/BRCA2 mutations) help to detect it earlier in higher-risk patients.
What factors influence survival?
The main factors are the tumor stage at diagnosis, the quality of the initial surgery (especially whether complete cytoreduction is achieved), tumor biology and histological subtype, the patient's genetic profile and the response to systemic treatment.
Why is it important to be treated in a specialised centre?
Because the team's experience and the volume of cases treated directly influence outcomes. Expert surgery and a multidisciplinary approach are key to survival, especially in complex surgeries with peritoneal involvement.
What treatments are currently available?
Treatment may include advanced oncological surgery with complete cytoreduction, chemotherapy (systemic or intraperitoneal), targeted therapies (PARP inhibitors, anti-angiogenic agents) and innovative strategies such as HIPEC. Molecular analysis also allows treatment to be personalised.
What is the most important factor in ovarian cancer treatment?
One of the most decisive factors is achieving complete tumor resection at the initial surgery, since it is the modifiable prognostic factor with the greatest impact on survival.
Is life expectancy the same for every patient?
No. It is currently understood as an individualised outcome that depends on multiple clinical, biological and therapeutic factors from the very first treatment decision. Two patients at the same stage can have very different prognoses depending on tumor biology, genetic profile and the centre where they are treated.
How has the prognosis changed in recent years?
Thanks to advances in cytoreductive surgery, targeted therapies (especially PARP inhibitors in BRCA-mutated patients) and molecular diagnosis, the approach has evolved towards personalised medicine that improves outcomes in many cases, particularly progression-free survival.
What sets an international reference centre apart?
The integration in a single multidisciplinary team of advanced surgery, specialised medical oncology, molecular diagnostics and access to innovative therapies and clinical trials. Continuity of care under the same team is what separates a good treatment from an excellent one.